Slide 1: Nicox Corporate Presentation
Nicox Corporate Presentation An international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health October 2022 September 2022
Slide 2: Forward-Looking Statements
Forward-Looking Statements This document has been prepared by Nicox SA and may not be reproduced or distributed, in whole or in part. The information contained in this document has not been independently verified and no representation, warranty or undertaking, expressed or implied, is made as to, an
Slide 3: Driving Innovation in Ophthalmology, Led by NCX 470 & an Experienced Team
Driving Innovation in Ophthalmology, Led by NCX 470 & an Experienced Team Differentiated pipeline Experienced Leadership, Cash position enhanced by with significant near-term Board and Advisors with global partnerships and out- clinical trial results from expertise to drive NICOX VISIBLE SCIENCE lic
Slide 4: Potential best-in-class profile in intraocular pressure lowering
Potential best-in-class profile in intraocular pressure lowering, the leading cause of glaucoma First pivotal Phase 3 topline results in early November 2022 NICOX VISIBLE SCIENCE Potential best-in- Large and established market1: NCXin470 class profile $6 billion globally Value Proposition intraocula
Slide 5: Broad Global Leadership Experience
Broad Global Leadership Experience NICOX VISIBLE SCIENCE Andreas Segerros Sandrine Gestin Doug Hubatsch Emmanuelle Pierry Gavin Spencer Chief Executive VP, Finance EVP, Chief Scientific Officer General Counsel & Head, EVP, Chief Business Officer & Officer Legal Head, Corporate Development Former mem
Slide 6: Board Bringing Extensive Experience in Ophthalmology and Pharmaceuticals
Board Bringing Extensive Experience in Ophthalmology and Pharmaceuticals JEAN-FRANÇOIS LABBE LES KAPLAN Chairman of the Board Director NICOX VISIBLE SCIENCE MICHELE GARUFI LAUREN SILVERNAIL Director Director ADRIENNE GRAVES LUZI VON BIDDER Director Director 6
Slide 7: Unique Combination of Competencies
Unique Combination of Competencies Capable of bringing NCX 470 to approval and driving future growth Corporate, Finance and Legal team have NICOX VISIBLE SCIENCE completed multiple transactions, restructuring and financing International R&D Management with deep ophthalmology experience World-recogni
Slide 8: 2022: A Year of Change and Opportunity
2022: A Year of Change and Opportunity Focus in on key, value Pivotal Phase 3 results New Chief Executive New Chief Scientific creating, innovative on lead asset due in Officer, Andreas Officer brings NICOX VISIBLE SCIENCE assets and evaluate November 2022, Segerros, brings ophthalmology additions t
Slide 9: Differentiated Pipeline Addresses Broad Ophthalmology Market
Differentiated Pipeline Addresses Broad Ophthalmology Market Stages of Development In-house Development Product Candidates Preclinical Phase 1 Phase 2 Phase 3 NDA Marketed Expected Milestones Topline results in early NCX 470 | novel NO-donating prostaglandin analog Mont Blanc Trial November 2022 Gla
Slide 10: NCX 470
NCX 470 Leveraging the potent intraocular pressure-lowering effects of nitric oxide and prostaglandin analogs for potential best-in-class treatment in glaucoma
Slide 11: Glaucoma Snapshot
Glaucoma Snapshot Elevated intraocular pressure (IOP) contributes to irreversible optic nerve damage, leading to progressive vision loss NICOX VISIBLE SCIENCE As published in the landmark EMGT study “…each mmHg of decreased IOP was related to an approximately 10% lowering [of risk of vision loss pro
Slide 12: Unmet Medical Need for Glaucoma Treatment
Unmet Medical Need for Glaucoma Treatment Despite having well established NICOX VISIBLE SCIENCE 40% of patients do Many patients Tolerability issues first line therapies, including the not achieve their require >1 with some standard of care, latanoprost, target IOP on medication which medications le
Slide 13: NCX 470 Targets the Two Key Outflow Pathways for IOP Lowering
NCX 470 Targets the Two Key Outflow Pathways for IOP Lowering Potential for best-in-class efficacy with proven dual mechanism of action Two pathways for Primary or conventional aqueous humor outflow 1 NICOX VISIBLE SCIENCE outflow normally Stimulated by accounts for ~60% to nitric oxide (NO) 80% of
Slide 14: NCX 470 Targets >$1 Billion U.S. Glaucoma Opportunity
NCX 470 Targets >$1 billion U.S. Glaucoma Opportunity Glaucoma: Approximately 3 million patients in the U.S. with open angle glaucoma1 progressive and First line, prostaglandin-based therapies represent a >$1 billion opportunity in the U.S. alone irreversible vision 40% of patients fail to reach tar
Slide 15: NCX 470 Market Potential in the U.S.
NCX 470 Market Potential in the U.S. Potential best-in-class therapeutic profile vs. standard of care (latanoprost) Existing Branded and Generic Based on market research3 on IOP lowering, Prostaglandin Analog (PGA) Label NCX 470 potential driven the by magnitude of NICOX VISIBLE SCIENCE Claims1 the
Slide 16: NCX 470 Dolomites Phase 2 Trial
NCX 470 Dolomites Phase 2 Trial Statistical superiority to standard of care in IOP lowering Mean Diurnal IOP Lowering from Phase 2 Dolomites Trial Summary Baseline 9 Met the primary non-inferiority endpoint of reduction from NICOX VISIBLE SCIENCE ** baseline in mean diurnal IOP at Day 28 in the 433-
Slide 17: NCX 470: Two Phase 3 Trials Support Planned U.S. & China NDA Submissions
NCX 470: Two Phase 3 Trials Support Planned U.S. & China NDA Submissions Mont Blanc topline results due in early November 2022 Both trials are randomized, controlled, double-masked, parallel design. Patients with open angle glaucoma or ocular hypertension were randomized 1:1 to once-daily treatment
Slide 18: NCX 470: Dual Mechanism of Action for Potent IOP lowering
NCX 470: Dual Mechanism of Action for Potent IOP lowering Potential to provide NICOX VISIBLE SCIENCE Promising Phase 2 First glaucoma Major Near-Term, best-in-class IOP data with higher monotherapy to be Clinical Value lowering, NCX 470 doses tested against Inflection Point: leveraging both demonstr
Slide 19: NCX 1728
NCX 1728 Novel class of molecules for IOP lowering and retinal conditions
Slide 20: NCX 1728: Lead Compound in a New Class of NO-donating Molecules
NCX 1728: Lead Compound in a New Class of NO-donating Molecules Combining NO- MOA* for this novel class of molecules is based entirely on NO-mediated activity release with PDE5 NO-mediated effects are enhanced and prolonged by concomitant phosphodiesterase-5 Inhibition (PDE5) inhibition within the s
Slide 21: NCX 1728: NO-Mediated IOP Lowering and Improved Ocular Perfusion
NCX 1728: NO-Mediated IOP Lowering and Improved Ocular Perfusion NCX 1728 NO-donating PDE5 inhibitor NICOX VISIBLE SCIENCE 2 1 Two potential target tissues for Improved ocular perfusion and reduced intraocular pressure NO-mediated effects 21 GTP = guanosine triphosphate, sGC = soluble guanylate cycl
Slide 22: NCX 4251
NCX 4251 Novel treatment with unique mode of application in dry eye disease
Slide 23: NCX 4251: Novel Approach to Dry Eye Disease
NCX 4251: Novel Approach to Dry Eye Disease Novel corticosteroid Novel, patented ophthalmic nanocrystal suspension of fluticasone propionate, a well-established presentation leverages corticosteroid. Fluticasone has 10x affinity for the glucocorticoid receptor vs. dexamethasone, Nicox’s unique commo
Slide 24: Mississippi: Post-Hoc Results Puts Dry Eye Disease in Sight
Mississippi: Post-Hoc Results Puts Dry Eye Disease in Sight Phase 2 Mississippi2 Trial Summary Unique eyelid margin The trial evaluated NCX 4251 in patients with acute application designed to exacerbations of blepharitis. Topline results of the trial minimize corticosteroid-induced did not meet prim
Slide 25: Nicox Corporate
Nicox Corporate nicox ©
Slide 26: U.S. Glaucoma Clinical Advisory Board with Leading Experts
U.S. Glaucoma Clinical Advisory Board with Leading Experts DR. ROBERT D. FECHTNER, MD, CHAIRMAN DR. STEVEN MANSBERGER, MD MPH Professor and Chair of the Department of Ophthalmology Vice-Chair, Senior Scientist, and Director of Glaucoma Services at SUNY Upstate Medical University, Syracuse, NY and Op
Slide 27: Partnering Deals Include Potential Future Payments & Royalties
Partnering Deals Include Potential Future Payments & Royalties Potential best-in-class treatment for IOP lowering NCX 470 6% to 12% royalties on future net sales1 in China and Southeast Asia Ocumension pays 50% of the Denali Phase 3 clinical trial costs NICOX VISIBLE SCIENCE First eye drop for glauc
Slide 28: Financial Highlights
Financial Highlights Cash balance expected to support current operations through November 30, 2023 Estimated Financial Position and Ownership as of September 30, 20221 Cash, Cash Equivalents €25.6 million NICOX VISIBLE SCIENCE Debt2 €20.6 million Cash runway3 November 30, 2023 Outstanding Shares4 43
Slide 29: Value-Creating Milestones
Value-Creating Milestones Building a high-value ophthalmology pipeline NICOX VISIBLE SCIENCE Q1 2022 Q2 2022 November 2022 NCX 4251 Move into ZERVIATE Phase 3 NCX 470 Mont Blanc DED following US FDA completed in China Phase 3 topline results meeting V Q1 2022 Q2 2022 After 2024 NCX 470 Phase 3 Mont
Slide 30: Nicox S.A. contact details
Nicox S.A. Nicox Research Institute S.r.l. Nicox Ophthalmics, Inc. Drakkar 2 – Bât. D 4819 Emperor Blvd. Suite 400 Via Ariosto 21 2405 Route des Dolines Durham, NC 27703, U.S 20091 Bresso 06560 Valbonne, France Milano, Italy T. +1 984 710 5354. T: +33 (0)4 97 24 53 00 T: +39 02 61 03 61 F: +33 (0)4